<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680637</url>
  </required_header>
  <id_info>
    <org_study_id>20200234</org_study_id>
    <nct_id>NCT04680637</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects&#xD;
      with active systemic lupus erythematosus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">June 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants Achieving a Systemic Lupus Erythematosus Responder Index-4 (SRI-4) Response at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>SRI-4 response is defined as a greater than or equal to 4-point decrease in the hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score and no new British Isles Lupus Assessment Group (BILAG) 2004 A domain score and no greater than 1 new BILAG 2004 B scores compared with baseline; and a less than 0.3-point deterioration from baseline in Physician Global Assessment (PGA) VAS (scale 0 to 3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving a British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 24 and Week 52</measure>
    <time_frame>Week 24 and Week 52</time_frame>
    <description>BICLA response is defined as at least 1 gradation of improvement in baseline British Isles Lupus Assessment Group (BILAG) domain scores in all body systems with moderate or severe disease activity at entry (eg, all A [severe disease] domain scores falling to B [moderate], C [mild], or D [no activity], and all B domain scores falling to C or D); no new BILAG 2004 A domain score and no greater than 1 new BILAG 2004 B domain scores compared with baseline; less than 0.3-point deterioration from baseline in Physician Global Assessment (PGA) (scale 0 to 3); and no initiation of non-protocol treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving a Lupus Low Disease Activity State (LLDAS) Response at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>LLDAS response is defined as a hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score ≤ 4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, and fever) and no haemolytic anaemia or gastrointestinal activity; no new findings of lupus disease activity compared with the previous assessment; ≤ 1-point in Physician Global Assessment (PGA) (scale 0 to 3) current prednisolone-equivalent dosage ≤ 7.5 mg/day; and standard maintenance dosages of immunosuppressive drugs and approved biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants with a Reduction of Oral Corticosteroid (OCS) to Less Than or Equal to 7.5 mg/day by Week 44 and Sustained Through Week 52 in Participants with a Baseline OCS Dose ≥ 10 mg/day</measure>
    <time_frame>Week 52</time_frame>
    <description>To evaluate the efficacy of efavaleukin alfa with oral corticosteroid (OCS)-tapering in subjects with SLE with inadequate response to SOC therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving a Systemic Lupus Erythematosus Responder Index-4 (SRI-4) Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>SRI-4 response is defined as a greater than or equal to 4-point decrease in the hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score; no new British Isles Lupus Assessment Group (BILAG) 2004 A domain score and no greater than 1 new BILAG 2004 B scores compared with baseline; and a less than 0.3-point deterioration from baseline in Physician Global Assessment (PGA) (scale 0 to 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving a Hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) Response at Week 24 and Week 52</measure>
    <time_frame>Week 24 and Week 52</time_frame>
    <description>hSLEDAI response is defined as a greater than or equal to 4-point decrease in score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender and Swollen Joint Count ≥ 50% Improvement from Baseline at Weeks 8, 12, 24, 36, and 52 in Participants with ≥ 6 Tender and Swollen Joints Involving the Hands and Wrists at Baseline</measure>
    <time_frame>Baseline, Week 8, 12, 24, 36, and 52</time_frame>
    <description>A 28-joint count will be used to evaluate the effect of efavaleukin alfa on additional SLE efficacy endpoints. A total 28 joints will be scored for presence or absence of swelling. A separated score for joints in the hands and wrists will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cutaneous Lupus Erythematosus Area and Severity Index (CLASI) Activity Score ≥ 50% Improvement from Baseline at Week 8, 12, 24, 36, and 52 in Participants with a CLASI Activity Score ≥ 8 at Baseline</measure>
    <time_frame>Baseline, Week 8, 12, 24, 36, and 52</time_frame>
    <description>To evaluate the effect of efavaleukin alfa on additional SLE efficacy endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants who Experience a Flare</measure>
    <time_frame>Week 52</time_frame>
    <description>A flare is defined as a British Isles Lupus Assessment Group (BILAG) score designation of 'worse' or 'new'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient-Reported Outcome Measurement Information System Fatigue Short Form 7a Instrument (PROMIS Fatigue SF 7A) Fatigue Score</measure>
    <time_frame>Baseline, Week 12, 24, 36, and 52</time_frame>
    <description>To describe the effect of treatment with efavaleukin alfa using patient reported outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Medical Outcomes Short Form-36 Questionnaire Score</measure>
    <time_frame>Baseline, Week 12, 24, 36, and 52</time_frame>
    <description>To describe the effect of treatment with efavaleukin alfa using patient reported outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lupus Quality of Life (QoL) Questionnaire Score</measure>
    <time_frame>Baseline, Week 12, 24, 36, and 52</time_frame>
    <description>To describe the effect of treatment with efavaleukin alfa using patient reported outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Experience a Treatment-Emergent Adverse Event (AE) and Serious Adverse Event (SAE)</measure>
    <time_frame>Up to Week 56</time_frame>
    <description>To characterize the safety of efavaleukin alfa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Experience a Clinically Significant Change in Laboratory Values and Vital Sign Measurements</measure>
    <time_frame>Up to Week 56</time_frame>
    <description>To characterize the safety of efavaleukin alfa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Serum and Sparse Postdose Serum Concentration of Efavaleukin Alfa</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>To characterize the pharmacokinetics (PK) of efavaleukin alfa.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Active Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Placebo + Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavaleukin Alfa Dose Level One + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavaleukin Alfa Dose Level Two + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavaleukin Alfa Dose Level Three + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavaleukin Alfa</intervention_name>
    <description>Administered as a subcutaneous (SC) injection.</description>
    <arm_group_label>Efavaleukin Alfa Dose Level One + Standard of Care</arm_group_label>
    <arm_group_label>Efavaleukin Alfa Dose Level Three + Standard of Care</arm_group_label>
    <arm_group_label>Efavaleukin Alfa Dose Level Two + Standard of Care</arm_group_label>
    <other_name>AMG 592</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as a subcutaneous (SC) injection.</description>
    <arm_group_label>Placebo + Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.</description>
    <arm_group_label>Efavaleukin Alfa Dose Level One + Standard of Care</arm_group_label>
    <arm_group_label>Efavaleukin Alfa Dose Level Three + Standard of Care</arm_group_label>
    <arm_group_label>Efavaleukin Alfa Dose Level Two + Standard of Care</arm_group_label>
    <arm_group_label>Placebo + Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has provided informed consent prior to initiation of any study specific&#xD;
             activities/procedures.&#xD;
&#xD;
          -  Participant is aged between 18 and 75.&#xD;
&#xD;
          -  Fulfills classification criteria for systemic lupus erythematosus (SLE) according to&#xD;
             the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology&#xD;
             (ACR) classification criteria for SLE with antinuclear antibody ≥ 1:80 by&#xD;
             immunofluorescence on Hep-2 cells being present at screening.&#xD;
&#xD;
          -  Hybrid SLEDAI score ≥ 6 points with a &quot;Clinical&quot; hSLEDAI score ≥ 4 points. The&#xD;
             &quot;Clinical&quot; hSLEDAI is the hSLEDAI assessment score without the inclusion of points&#xD;
             attributable to laboratory results, including urine or immunologic parameters.&#xD;
&#xD;
          -  British-Isles Lupus Assessment Group (BILAG) index score (BILAG 2004) of ≥ 1 A item or&#xD;
             ≥ 2 B items.&#xD;
&#xD;
          -  Must be taking ≥ 1 of the following SLE treatments (or regional equivalent):&#xD;
             hydroxychloroquine, chloroquine, quinacrine, mycophenolate mofetil, azathioprine,&#xD;
             methotrexate, dapsone, or oral calcineurin inhibitors, or OCS. A participant may enter&#xD;
             the study on OCS alone (prednisone ≥ 10 mg/day or equivalent) only if the participant&#xD;
             has previously documented trial of anti-malarial or immunosuppressant treatment for&#xD;
             SLE. Participants must be on a stable dose for ≥ 8 weeks prior to screening for all&#xD;
             antimalarials and immunosuppressants, with the exception of OCS doses which must be&#xD;
             stable for ≥ 2 weeks prior to screening.&#xD;
&#xD;
          -  For participants taking OCS, dose must be ≤ 20 mg/day of prednisone or OCS equivalent,&#xD;
             and the dose must be stable at baseline visit and for ≥ 2 weeks prior to screening&#xD;
             visit.&#xD;
&#xD;
          -  Stability of SLE treatments: OCS and other immunosuppressants/immunomodulator agents&#xD;
             and doses must be stable since screening visit.&#xD;
&#xD;
          -  Disease activity: active disease as indicated by clinical hSLEDAI score ≥ 4 must be&#xD;
             observed (clinical hSLEDAI score is the hSLEDAI assessment score without the inclusion&#xD;
             of points attributable to laboratory results including urine and immunologic&#xD;
             parameters).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lupus nephritis if any of the following are present: urine protein creatinine ratio ≥&#xD;
             2000 mg/g (or equivalent) at screening, OR having required induction therapy within 1&#xD;
             year prior to screening, OR histological evidence (if available) of diffuse&#xD;
             proliferative glomerulonephritis within 12 weeks prior to screening.&#xD;
&#xD;
          -  Active CNS lupus within 1 year prior to screening including, but not limited to,&#xD;
             aseptic meningitis, ataxia, CNS vasculitis, cranial neuropathy, demyelinating&#xD;
             syndrome, optic neuritis, psychosis, seizures, or transverse myelitis.&#xD;
&#xD;
          -  Currently present or within 1 year prior to screening a diagnosis of any chronic&#xD;
             inflammatory disease other than SLE (eg, rheumatoid arthritis) which would interfere&#xD;
             with SLE disease assessment.&#xD;
&#xD;
          -  History of any disease other than SLE that has required treatment with oral or&#xD;
             parenteral corticosteroids for &gt; 2 weeks within 4 months prior to screening.&#xD;
&#xD;
          -  Active infection (including chronic or localized infections) for which anti-infectives&#xD;
             were indicated within 4 weeks prior to screening visit OR presence of serious&#xD;
             infection, defined as requiring hospitalization or intravenous anti-infectives within&#xD;
             8 weeks prior to screening visit.&#xD;
&#xD;
          -  Active tuberculosis or latent tuberculosis with no documented past history of adequate&#xD;
             treatment per local standard of care.&#xD;
&#xD;
          -  Positive test for tuberculosis during creening defined as: either a positive or&#xD;
             indeterminate QuantiFERON®-TB or T-spot test OR positive purified protein derivative&#xD;
             (PPD) (≥5 mm of induration at 48 to 72 hours after test is placed).&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen (HBsAg); or positive for hepatitis B core&#xD;
             antibody (HBcAb). A history of hepatitis B vaccination without history of hepatitis B&#xD;
             infection (ie, positive hepatitis B surface antibody (HBsAb), negative HBsAg and&#xD;
             negative HBcAb) is allowed.&#xD;
&#xD;
          -  Positive for hepatitis C antibody.&#xD;
&#xD;
          -  Known history of HIV or positive HIV test at screening.&#xD;
&#xD;
          -  Presence of 1 or more significant concurrent medical conditions, including but not&#xD;
             limited to the following:&#xD;
&#xD;
               -  poorly controlled diabetes (hemoglobin A1C &gt; 7) or hypertension&#xD;
&#xD;
               -  symptomatic heart failure (New York Heart Association class III or IV)&#xD;
&#xD;
               -  myocardial infarction or unstable angina pectoris within the past 12 months prior&#xD;
                  to screening&#xD;
&#xD;
               -  severe chronic pulmonary disease requiring oxygen therapy&#xD;
&#xD;
               -  multiple sclerosis or any other demyelinating disease&#xD;
&#xD;
          -  Any history of malignancy with the following exceptions:&#xD;
&#xD;
          -  resolved non-melanoma skin cancers &gt; 5 years prior to screening&#xD;
&#xD;
          -  resolved cervical carcinoma &gt; 5 years prior to screening&#xD;
&#xD;
          -  resolved breast ductal carcinoma in situ &gt; 5 years of screening&#xD;
&#xD;
          -  Currently receiving or had treatment with: cyclophosphamide, chlorambucil, nitrogen&#xD;
             mustard, or any other alkylating agent within 6 months prior to screening or sirolimus&#xD;
             within 4 weeks prior screening.&#xD;
&#xD;
          -  Currently receiving or had treatment with a Janus kinase (JAK) inhibitor within 3&#xD;
             months or less than 5 drug half-lives (whichever is longer) prior to screening.&#xD;
&#xD;
          -  Currently receiving or had treatment with an immune checkpoint inhibitor (eg,&#xD;
             programmed death 1 [PD-1] inhibitor, programmed death ligand 1 [PD-L1] inhibitor,&#xD;
             cytotoxic T-lymphocyte associated protein 4 [CTLA-4] inhibitor).&#xD;
&#xD;
        Note: Abatacept is not considered a CTLA-4 inhibitor and is referred to below.&#xD;
&#xD;
          -  Currently receiving or had treatment within 12 months prior to screening with T-cell&#xD;
             depleting agents (eg, antithymocyte globulin, Campath).&#xD;
&#xD;
          -  Currently receiving of had treatment with an interleukin 2 (IL-2) based therapy (eg,&#xD;
             Proleukin).&#xD;
&#xD;
          -  Current or previous treatment with a biologic agent as follows: rituximab within 6&#xD;
             months prior to screening; abatacept and belimumab within the past 3 months prior to&#xD;
             screening; other biologics within &lt; 5 drug half lives prior to screening.&#xD;
&#xD;
          -  Participants who have received intraarticular, intralesional, or intramuscular&#xD;
             corticosteroids within 2 weeks prior to screening or intravenous corticosteroids&#xD;
             within 6 weeks prior to screening.&#xD;
&#xD;
          -  Participants who have received live vaccines within 5 weeks prior to screening, or&#xD;
             plan to receive live vaccines during the treatment period and up to 6 weeks after the&#xD;
             end of treatment period in the study.&#xD;
&#xD;
          -  Currently receiving treatment in another investigational device or drug study.&#xD;
&#xD;
          -  Ending a treatment with an investigational drug or investigational device less than 3&#xD;
             months or 5 half-lives from the last dose of the investigational drug (whichever is&#xD;
             longer) at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham,Arthritis Clinical Intervention Program</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Associates PC</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis And Rheumatology Associates PC</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Associates PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robin K Dore MD Inc</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatic Disease Specialties</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Life Clinical Trials</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre for Rheumatology Immunology and Arthritis</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Millennium Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Integral Rheumatology and Immunology Specialists</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suncoast Medical Clinic</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baycare Medical Group Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greater Chicago Specialty Physicians</name>
      <address>
        <city>Schaumburg</city>
        <state>Illinois</state>
        <zip>60195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinic of Robert Hozman, MD - Clinical Investigational Specialists, Inc</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western Kentucky Rheumatology PLLC</name>
      <address>
        <city>Hopkinsville</city>
        <state>Kentucky</state>
        <zip>42240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan Rheumatology Group, PC - Grand Blanc Office</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Translation Research at Einstein and Montefiore Clinical Research Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Feinstein Institute for Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill Thurston Arthritis Research Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Joint and Muscle Research Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Javara</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atrium Health Rheumatology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatology Center of Oklahoma PLLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia Arthritis Center, PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Piedmont Arthritis Clinic</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute, LLC</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ramesh C Gupta MD</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precision Comprehensive Clinical Research Solutions</name>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trinity Universal Research Associates, LLC</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Clinic</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diagnostic-Consultative Center Sveti Georgi EOOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Excelsior OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Academy EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Athens Naval Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Attiko Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Olympion Hospital-General Clinic of Patras AE</name>
      <address>
        <city>Patra</city>
        <zip>26443</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ippokrateio Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Chibahigashi National Hospital</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Occupational and Environmental Health</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>807-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sapporo City General Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Marianna University School of Medicine Hospital</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Corporation Tohoku University Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seirei Hamamatsu General Hospital</name>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka</state>
        <zip>430-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Lukes International Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Tokyo Medical Center</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic Universtiy Medcial Center</name>
      <address>
        <city>Daegu</city>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si, Gyeonggi-do</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eukarya Pharmasite sc</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64718</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spolka Lekarzy Intercor Spzoo</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-605</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Czestochowa</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ MED-ROZ Kazimierz Rozumek Grzegorz Rozumek Joanna Peksyk spolka jawna</name>
      <address>
        <city>Karwiany</city>
        <zip>52-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych Wojciech Brzezicki</name>
      <address>
        <city>Malbork</city>
        <zip>82-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ Lecznica MAK-MED sc</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabinety Lekarskie RIVERMED</name>
      <address>
        <city>Poznan</city>
        <zip>61-441</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucía</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Cataluña</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Araba</name>
      <address>
        <city>Vitoria</city>
        <state>País Vasco</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St Gallen</name>
      <address>
        <city>St Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cukurova Universitesi Balcali Hastanesi Saglik Uygulama ve Arastirma Merkezi</name>
      <address>
        <city>Adana</city>
        <zip>01790</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akdeniz Universitesi Tip Fakultesi</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

